NEWS RELEASES

The information contained in each news release on this page was factually accurate on the date it was issued and posted. 

Sutro Biopharma Announces $85.0 Million Initial Public Offering

South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF+™, to create a broad...

read more

Sutro Biopharma Announces $85.4 Million Series E Round

Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its...

read more

Sutro Marks Two Drug Development Milestones

Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first...

read more